Program: Oral and Poster Abstracts
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I
Patients and Methods: All patients signed a written informed consent and data analysis was approved by our IRB. In the outpatient setting, a single cycle of metro-28 comprised DOX and DDP each at 1.0mg/m2/d for 28d by continuous infusion (CI), along with VTD (bortezomib 1.0mg/m2 on days 1-4, 7-10, 13-16, 19-22, 25-28; DEX 12mg on days 1-4, 7-10, 13-16, 19-22, 25-28; thalidomide 50-100mg/d x 28d; some patients also received vincristine [VCR] at a flat daily dose of 0.07mg/d x 28d by CI.
Results: Fourteen patients were initiated on metro-28. Their characteristics included age >=65y in 12; albumin <3.5g/dL in 8; B2M >5.5mg/L in 7; cytogenetic abnormalities [CA] were present in 10; GEP70 HRMM in 9/13; PR subgroup in 8/13 (Table 1). The median follow up is 11mo. As portrayed in Figure 1A, no patient has died; the 6mo PFS estimate was 85% (Figure 1B); responses included CR in 3/14, VGPR in 7/14 and PR in 10/14 (Figure 1C); and the PR duration estimate at 6mo is 80% (Figure 1D). Of interest, GEP70 scores morphed to low risk in 3/13. Vascular density (CD34) decreased markedly in most patients evaluated. Toxicities were minor; myelosuppression was virtually absent; alopecia was not encountered. Subsequent salvage therapies included repeat metro-28, combination chemotherapy (PACMED) and autotransplants.
Conclusion: We conclude that metro-28 is a promising and safe strategy for elderly patients with HRMM, and we hypothesize an anti-angiogenic mechanism of action in addition to direct anti-MM effects.
Table 1: Patient characteristics
Factor |
n/N (%) |
Age >= 65 yr |
12/14 (86%) |
Albumin < 3.5 g/dL |
8/14 (57%) |
B2M >= 3.5 mg/L |
9/12 (75%) |
B2M > 5.5 mg/L |
7/12 (58%) |
Hb < 10 g/dL |
10/14 (71%) |
Cytogenetic Abnormalities |
10/14 (71%) |
CA within 1 Year of Therapy |
10/14 (71%) |
CA within 90 Days of Therapy |
9/14 (64%) |
GEP 70-Gene High Risk |
9/13 (69%) |
GEP PR Subgroup |
8/13 (62%) |
GEP Proliferation Index >= 10 |
7/13 (54%) |
GEP Centrosome Index >= 3 |
7/13 (54%) |
n/N (%): n- Number with factor, N- Number with valid data for factor |
Figure 1
Disclosures: Thanendrarajan: University of Arkansas for Medical Sciences: Employment . Alapat: University of Arkansas for Medical Sciences: Employment . Zangari: University of Arkansas for Medical Sciences: Employment ; Onyx: Research Funding ; Millennium: Research Funding ; Novartis: Research Funding . Schinke: University of Arkansas for Medical Sciences: Employment . Heuck: Millenium: Other: Advisory Board ; Janssen: Other: Advisory Board ; Foundation Medicine: Honoraria ; Celgene: Consultancy ; University of Arkansas for Medical Sciences: Employment . van Rhee: University of Arkansa for Medical Sciences: Employment . Rosenthal: Cancer Research and Biostatistics: Employment . Epstein: University of Arkansas for Medical Sciences: Employment . Yaccoby: University of Arkansas for Medical Sciences: Employment . Davies: Janssen: Consultancy ; Onyx: Consultancy ; University of Arkansas for Medical Sciences: Employment ; Millenium: Consultancy ; Celgene: Consultancy . Morgan: MMRF: Honoraria ; Takeda: Honoraria , Membership on an entity’s Board of Directors or advisory committees ; CancerNet: Honoraria ; Bristol Myers Squibb: Honoraria , Membership on an entity’s Board of Directors or advisory committees ; Weismann Institute: Honoraria ; Celgene: Honoraria , Membership on an entity’s Board of Directors or advisory committees ; University of Arkansas for Medical Sciences: Employment . Barlogie: University of Arkansas for Medical Sciences: Employment .
See more of: Myeloma: Therapy, excluding Transplantation
See more of: Oral and Poster Abstracts
*signifies non-member of ASH